Moderna’s COVID-19 vaccine under expert panel review

 

• The expert panel evaluating the COVID-19 vaccine candidate from Moderna (NASDAQ:MRNA) has started the proceedings.
• The meeting by the Vaccines and Related Biological Products Advisory Committee will run until 5:15 p.m.ET with a vote, that typically happens towards the end of the meeting, potentially clearing the way for Moderna to seek the emergency authorization from the FDA.
• Last week, the expert panel voted 17 to 4 to recommend the COVID-19 vaccine from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), with the FDA granting the EUA a day later. Though the FDA is not bound by the recommendation, it often follows the guidance.
• Packaged and delivered by McKesson (NYSE:MCK), nearly 6 million doses of Moderna’s vaccine will reach 3,285 sites in the U.S. following the approval, according to officials.
• Moderna’s briefing documents filed earlier this week included data showing the vaccine’s first dose had yielded efficacy in preventing asymptomatic infection, a vital characteristic to contain the pandemic.
• A researcher from Pfizer had said last week its vaccine’s ability to prevent asymptomatic cases was under investigation, and the analysis could be complete in early 2021.
• The prevention of asymptomatic cases will be vital to contain the pandemic that has so far claimed more than 300,000 lives in the U.S.
• https://seekingalpha.com/news/3645334-moderna-s-covidminus-19-vaccine-goes-under-review